30 results on '"Omerovic, Elmir"'
Search Results
2. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
- Author
-
Collet, Jean-Philippe, Thiele, Holger, Barbato, Emanuele, Barthélémy, Olivier, Bauersachs, Johann, Bhatt, Deepak, Dendale, Paul, Dorobantu, Maria, Edvardsen, Thor, Folliguet, Thierry, Gale, Chris, Gilard, Martine, Jobs, Alexander, Jüni, Peter, Lambrinou, Ekaterini, Lewis, Basil, Mehilli, Julinda, Meliga, Emanuele, Merkely, Béla, Mueller, Christian, Roffi, Marco, Rutten, Frans, Sibbing, Dirk, Siontis, George, Kastrati, Adnan, Mamas, Mamas, Aboyans, Victor, Angiolillo, Dominick, Bueno, Hector, Bugiardini, Raffaele, Byrne, Robert, Castelletti, Silvia, Chieffo, Alaide, Cornelissen, Veronique, Crea, Filippo, Delgado, Victoria, Drexel, Heinz, Gierlotka, Marek, Halvorsen, Sigrun, Haugaa, Kristina Hermann, Jankowska, Ewa, Katus, Hugo, Kinnaird, Tim, Kluin, Jolanda, Kunadian, Vijay, Landmesser, Ulf, Leclercq, Christophe, Lettino, Maddalena, Meinila, Leena, Mylotte, Darren, Ndrepepa, Gjin, Omerovic, Elmir, Pedretti, Roberto, Petersen, Steffen, Petronio, Anna Sonia, Pontone, Gianluca, Popescu, Bogdan, Potpara, Tatjana, Ray, Kausik, Luciano, Flavio, Richter, Dimitrios, Shlyakhto, Evgeny, Simpson, Iain, Sousa-Uva, Miguel, Storey, Robert, Touyz, Rhian, Valgimigli, Marco, VRANCKX, PASCAL, Yeh, Robert, Collet, Jean-Philippe, Thiele, Holger, Barbato, Emanuele, Barthélémy, Olivier, Bauersachs, Johann, Bhatt, Deepak L, Dendale, Paul, Dorobantu, Maria, Edvardsen, Thor, Folliguet, Thierry, Gale, Chris P, Gilard, Martine, Jobs, Alexander, Jüni, Peter, Lambrinou, Ekaterini, Lewis, Basil S, Mehilli, Julinda, Meliga, Emanuele, Merkely, Béla, Mueller, Christian, Roffi, Marco, Rutten, Frans H, Sibbing, Dirk, Siontis, George C M, Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Institute of cardiometabolism and nutrition (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut de cardiologie [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Collet J.-P., Thiele H., Barbato E., Bauersachs J., Dendale P., Edvardsen T., Gale C.P., Jobs A., Lambrinou E., Mehilli J., Merkely B., Roffi M., Sibbing D., Kastrati A., Mamas M.A., Aboyans V., Angiolillo D.J., Bueno H., Bugiardini R., Byrne R.A., Castelletti S., Chieffo A., Cornelissen V., Crea F., Delgado V., Drexel H., Gierlotka M., Halvorsen S., Haugaa K.H., Jankowska E.A., Katus H.A., Kinnaird T., Kluin J., Kunadian V., Landmesser U., Leclercq C., Lettino M., Meinila L., Mylotte D., Ndrepepa G., Omerovic E., Pedretti R.F.E., Petersen S.E., Petronio A.S., Pontone G., Popescu B.A., Potpara T., Ray K.K., Luciano F., Richter D.J., Shlyakhto E., Simpson I.A., Sousa-Uva M., Storey R.F., Touyz R.M., Valgimigli M., Vranckx P., Yeh R.W., Barthelemy O., Bhatt D.L., Dorobantu M., Folliguet T., Gilard M., Juni P., Lewis B.S., Meliga E., Mueller C., Rutten F.H., and Siontis G.C.M.
- Subjects
unstable angina ,Myocardial ischaemia ,[SDV]Life Sciences [q-bio] ,Vascular damage Radboud Institute for Health Sciences [Radboudumc 16] ,dual antithrombotic therapy ,Guideline ,heparin ,030204 cardiovascular system & hematology ,Platelet inhibition ,antiplatelet ,0302 clinical medicine ,ST segment ,Medicine ,dabigatran ,Myocardial infarction ,guidelines ,glycoprotein iib/iiia inhibitors ,anticoagulation ,Non-ST Elevated Myocardial Infarction ,rivaroxaban ,ComputingMilieux_MISCELLANEOUS ,reproductive and urinary physiology ,diabetes ,bleedings ,bivalirudin ,atherothrombosi ,Disease Management ,angioplasty ,Guidelines • acute cardiac care • acute coronary syndrome • angioplasty • anticoagulation • antiplatelet • apixaban • aspirin • atherothrombosis • betablockers • bleedings • bivalirudin • bypass surgery • cangrelor • chest pain unit • clopidogrel • dabigatran • diabetes • dual antithrombotic therapy • early invasive strategy • edoxaban • enoxaparin • European Society of Cardiology • fondaparinux • glycoprotein IIb/ IIIa inhibitors • heparin • high-sensitivity troponin • minoca • myocardial ischaemia • myocardial infarction • nitrates • non-ST-elevation myocardial infarction • platelet inhibition • prasugrel • recommendations • revascularization • rhythm monitoring • rivaroxaban • stent • ticagrelor • triple therapy • unstable angina ,enoxaparin ,General Medicine ,Clopidogrel ,3. Good health ,early invasive strategy ,myocardial infarction ,triple therapy ,030220 oncology & carcinogenesis ,High sensitivity troponin ,embryonic structures ,Cardiology ,Platelet aggregation inhibitor ,revascularization ,biological phenomena, cell phenomena, and immunity ,Cardiology and Cardiovascular Medicine ,Ticagrelor ,medicine.drug ,Human ,recommendation ,Acute coronary syndrome ,medicine.medical_specialty ,aspirin ,glycoprotein IIb/IIIa inhibitor ,non-ST-elevation myocardial infarction ,apixaban ,rhythm monitoring ,European Society of Cardiology ,ticagrelor ,03 medical and health sciences ,nitrate ,atherothrombosis ,betablockers ,Internal medicine ,acute cardiac care ,minoca ,chest pain unit ,Diseases of the circulatory (Cardiovascular) system ,Humans ,In patient ,Acute Coronary Syndrome ,clopidogrel ,Unstable angina ,urogenital system ,nitrates ,business.industry ,fondaparinux ,betablocker ,Arrhythmias, Cardiac ,030229 sport sciences ,bleeding ,medicine.disease ,myocardial ischaemia ,platelet inhibition ,prasugrel ,diabete ,Glycoprotein IIb/IIIa inhibitors ,RC666-701 ,bypass surgery ,Settore MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLARE ,recommendations ,edoxaban ,high-sensitivity troponin ,stent ,business ,Platelet Aggregation Inhibitors ,cangrelor - Abstract
2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
- Published
- 2021
- Full Text
- View/download PDF
3. Sex differences in prevalence and characteristics of imaging detected atherosclerosis - a population-based study.
- Author
-
Swahn E, Sederholm Lawesson S, Alfredsson J, Fredrikson M, Angerås O, Duvernoy O, Engström G, Eriksson MJ, Fagman E, Johansson B, Johnson L, Johnston N, Ljungberg J, Mannila M, Nordendahl M, Oldgren J, Omerovic E, Ostenfeld E, Persson M, Rosengren A, Skoglund Larsson L, Sundström J, Söderberg M, Östgren CJ, Leander K, and Jernberg T
- Abstract
Aims: Men are more likely to suffer a myocardial infarction than women, but population-based studies on sex differences in imaging detected atherosclerosis are lacking. The aims were to assess sex differences in prevalence of imaging detected coronary and carotid atherosclerosis, as well as multivariable adjusted associations between sex and atherosclerosis., Methods and Results: Participants aged 50-65, recruited from the general population to the Swedish Cardiopulmonary bioImage Study (SCAPIS), were included in this population-based cross-sectional study. Comprehensive diagnostics, including coronary computed tomography angiography and carotid ultrasound, were performed. The image findings were any coronary atherosclerosis, coronary stenosis ≥50%, segment involvement score (SIS) ≥4, coronary artery calcium score (CACS) ≥100, and any ultrasound-detected carotid plaque.In 25,580 participants (50% women), men had more hypertension (20.3% vs 17.0%), hyperlipidaemia (9.0% vs 5.5%), and diabetes (8.5% vs 4.7%). The prevalence was 56.2% vs 29.5% for any coronary atherosclerosis (p<0.01), 9.0% vs 2.3% for coronary stenosis ≥50% (p<0.01), 20.2% vs 5.3% for SIS≥4 (p<0.01), 18.2% vs 5.6% for CACS≥100 (p<0.01), and 60.9% vs 48.7% for carotid plaque (p<0.01), in men vs women, respectively. Multivariable adjustment only marginally changed these associations: odds ratios [OR] (95% confidence interval [CI]): 2.75 (2.53-2.99) for coronary atherosclerosis, 2.88 (2.40-3.45) for coronary stenosis ≥50%, 3.99 (3.50-4.55) for SIS≥4, 3.29 (2.88-3.75), for CACS≥100, and 1.57 (1.45-1.70) for carotid plaque., Conclusion: Men had higher prevalence of imaging detected carotid and coronary atherosclerosis with prevalence in women aged 65 corresponding to men 10-14 years younger. The associations remained after extensive multivariable adjustment., (© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.)
- Published
- 2024
- Full Text
- View/download PDF
4. Observational studies are needed to complete the body of evidence for left main coronary artery disease revascularization strategies.
- Author
-
Persson J, Ivert T, and Omerovic E
- Subjects
- Humans, Coronary Artery Bypass, Treatment Outcome, Coronary Artery Disease surgery, Percutaneous Coronary Intervention
- Published
- 2023
- Full Text
- View/download PDF
5. Coronary calcification in patients presenting with acute coronary syndromes: insights from the MATRIX trial.
- Author
-
Sanz-Sanchez J, Garcia-Garcia HM, Branca M, Frigoli E, Leonardi S, Gagnor A, Calabrò P, Garducci S, Rubartelli P, Briguori C, Andò G, Repetto A, Limbruno U, Garbo R, Sganzerla P, Russo F, Lupi A, Cortese B, Ausiello A, Ierna S, Esposito G, Santarelli A, Sardella G, Varbella F, Tresoldi S, de Cesare N, Rigattieri S, Zingarelli A, Tosi P, van 't Hof A, Boccuzzi G, Omerovic E, Sabaté M, Heg D, Vranckx P, and Valgimigli M
- Subjects
- Humans, Coronary Artery Bypass, Myocardial Infarction complications, Percutaneous Coronary Intervention methods, Randomized Controlled Trials as Topic, Risk Factors, Stroke etiology, Treatment Outcome, Acute Coronary Syndrome complications, Acute Coronary Syndrome diagnosis, Acute Coronary Syndrome epidemiology, Coronary Artery Disease complications, Coronary Artery Disease diagnosis, Coronary Artery Disease surgery
- Abstract
Aims: The role of coronary calcification on clinical outcomes among different revascularization strategies in patients presenting with acute coronary syndromes (ACSs) has been rarely investigated. The aim of this investigation is to evaluate the role of coronary calcification, detected by coronary angiography, in the whole spectrum of patients presenting with acute ACS., Methods and Results: The present study was a post hoc analysis of the MATRIX programme. The primary endpoint was major adverse cardiovascular events (MACE), defined as the composite of all-cause mortality, myocardial infarction (MI), or stroke up to 365 days. Among the 8404 patients randomized in the MATRIX trial, data about coronary calcification were available in 7446 (88.6%) and therefore were included in this post hoc analysis. Overall, 875 patients (11.7%) presented with severe coronary calcification, while 6571 patients (88.3%) did not present severe coronary calcification on coronary angiography. Fewer patients with severe coronary calcification underwent percutaneous coronary intervention whereas coronary artery bypass grafting or medical therapy-only was more frequent compared with patients without severe calcification. At 1-year follow-up, MACE occurred in 237 (27.1%) patients with severe calcified coronary lesions and 985 (15%) patients without severe coronary calcified lesions [hazard ratio (HR) 1.91; 95% confidence interval (CI) 1.66-2.20, P < 0.001]. All-cause mortality was 8.6% in patients presenting with and 3.7% in those without severe coronary calcification (HR 2.38, 1.84-3.09, P < 0.001). Patients with severe coronary calcification incurred higher rate of MI (20.1% vs. 11.5%, HR 1.81; 95% CI 1.53-2.1, P < 0.001) and similar rate of stroke (0.8% vs. 0.6%, HR 1.35; 95% CI 0.61-3.02, P = 0.46)., Conclusion: Patients with ACS and severe coronary calcification, as compared to those without, are associated with worse clinical outcomes irrespective of the management strategy., Competing Interests: Conflict of interest: J.S.S. has received minor speaking honoraria from Terumo, Cordis, Biotronik, and Medtronic. H.M.G.-G. reports the following institutional grant support: Biotronik, Boston Scientific, Medtronic, Abbott, Neovasc, Shockwave, Phillips, and Corflow. G.A. reports minor speaking honoraria from Chiesi, Daiichi Sankyo, Boeringer Ingelheim, Bayer, Pfizer, and Biosensors. D.H. has participated on data safety monitoring board or advisory board of switch. S.L. has received consulting fees from AstraZeneca, Bayer, BMS/Pfizer, Chiesi, Daiichi-Sankyo, Icon, and Novonordisk. M.S. has received consulting fees from Abbott Vascular and iVascular. A.v.H. reports unrestricted grants from Medtronic, Abbott Vascular, and Boehringer Ingelheim and consulting fees from Celecor Therapeutics. P.V. reports consulting fees from Daiichi Sankyo, CSL Behring, Pfizer/Bristol Meyers Squibb alliance, Bayer AG, and Novartis; minor speaking honoraria from Daicchi Sankyo and Pfizer/Bristol Meyers Squibb alliance. M.V. reports consulting fees from Abbott, Alvimedica, Bayer Healthcare, Biotronik, Boston Scientific Corporation, Chiesi Farmaceutici, CoreFlow, Daiichi Sankyo, Idorsia, Medtronic, Novartis Pharma, PHASEBIO, Terumo, University of Basel, Vesalio, and Vifor Pharma. The rest of authors have no disclosures to declare., (© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2023
- Full Text
- View/download PDF
6. Comparison between ticagrelor and clopidogrel in myocardial infarction patients with high bleeding risk.
- Author
-
Tjerkaski J, Jernberg T, Alfredsson J, Erlinge D, James S, Lindahl B, Mohammad MA, Omerovic E, Venetsanos D, and Szummer K
- Subjects
- Humans, Ticagrelor adverse effects, Clopidogrel adverse effects, Platelet Aggregation Inhibitors adverse effects, Hemorrhage chemically induced, Ischemia drug therapy, Myocardial Infarction, Stroke epidemiology
- Abstract
Aims: Ticagrelor is associated with a lower risk of ischemic events than clopidogrel. However, it is uncertain whether the benefits of more intensive anti-ischemic therapy outweigh the risks of major bleeding in patients who have a high bleeding risk (HBR). Therefore, this study compared ticagrelor and clopidogrel in myocardial infarction (MI) patients with HBR., Methods and Results: This study included all patients enrolled in the SWEDEHEART registry who were discharged with dual antiplatelet therapy using ticagrelor or clopidogrel following MI between 2010 and 2017. High bleeding risk was defined as a PRECISE-DAPT score ≥25. Information on ischemic events, major bleeding, and mortality was obtained from national registries, with 365 days of follow-up. Additional outcomes include major adverse cardiovascular events (MACE), a composite of MI, stroke and all-cause mortality, and net adverse clinical events (NACE), a composite of MACE and bleeding. This study included 25 042 HBR patients, of whom 11 848 were treated with ticagrelor. Ticagrelor was associated with a lower risk of MI, stroke, and MACE, but a higher risk of bleeding compared to clopidogrel. There were no significant differences in mortality and NACE. Additionally, when examining the relationship between antiplatelet therapy and bleeding risk in 69 040 MI patients, we found no statistically significant interactions between the PRECISE-DAPT score and treatment effect., Conclusions: We observed no difference in NACE when comparing ticagrelor and clopidogrel in HBR patients. Moreover, we found no statistically significant interactions between bleeding risk and the comparative effectiveness of clopidogrel and ticagrelor in a larger population of MI patients., (© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.)
- Published
- 2023
- Full Text
- View/download PDF
7. PCI or CABG for left main coronary artery disease: the SWEDEHEART registry.
- Author
-
Persson J, Yan J, Angerås O, Venetsanos D, Jeppsson A, Sjögren I, Linder R, Erlinge D, Ivert T, and Omerovic E
- Subjects
- Humans, Treatment Outcome, Coronary Artery Bypass methods, Registries, Coronary Artery Disease therapy, Percutaneous Coronary Intervention methods, Diabetes Mellitus epidemiology, Stroke epidemiology, Stroke etiology
- Abstract
Aims: An observational nationwide all-comers prospective register study to analyse outcomes after coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) in unprotected left main coronary artery (LMCA) disease., Methods and Results: All patients undergoing coronary angiography in Sweden are registered in the Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies registry. Between 01/01/2005 and 12/31/2015, 11 137 patients with LMCA disease underwent CABG (n = 9364) or PCI (n = 1773). Patients with previous CABG, ST-elevation myocardial infarction (MI) or cardiac shock were excluded. Death, MI, stroke, and new revascularization during follow-up until 12/31/2015 were identified using national registries. Cox regression with inverse probability weighting (IPW) and an instrumental variable (IV), administrative region, were used. Patients undergoing PCI were older, had higher prevalence of comorbidity but lower prevalence of three-vessel disease. PCI patients had higher mortality than CABG patients after adjustments for known cofounders with IPW analysis (hazard ratio [HR] 2.0 [95% confidence interval (CI) 1.5-2.7]) and known/unknown confounders with IV analysis (HR 1.5 [95% CI 1.1-2.0]). PCI was associated with higher incidence of major adverse cardiovascular and cerebrovascular events (MACCE; death, MI, stroke, or new revascularization) than CABG, with IV analysis (HR 2.8 [95% CI 1.8-4.5]). There was a quantitative interaction for diabetic status regarding mortality (P = 0.014) translating into 3.6 years (95% CI 3.3-4.0) longer median survival time favouring CABG in patients with diabetes., Conclusion: In this non-randomized study, CABG in patients with LMCA disease was associated with lower mortality and fewer MACCE compared to PCI after multivariable adjustment for known and unknown confounders., Competing Interests: Conflict of interest J.P. has received unrestricted grants from Abbott Inc., unrelated to the present work. J.Y. has no conflicts of interest. O.A. has received research grant and lecture fees from Abbott Inc. D.V. has no conflicts of interest. A.J. has received fees for consultancy or lectures from AstraZeneca, Werfen, Portola, Baxter and LFB Biotechnologies, all unrelated to the present work. I.S. has no conflicts of interest. R.L. has no conflicts of interest. D.E. has no conflicts of interest. T.I. has no conflicts of interest. E.O. has no conflicts of interest., (© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.)
- Published
- 2023
- Full Text
- View/download PDF
8. Differences between cardiac troponin I vs. T according to the duration of myocardial ischaemia.
- Author
-
Espinosa AS, Hussain S, Al-Awar A, Jha S, Elmahdy A, Kalani M, Kakei Y, Zulfaj E, Aune E, Poller A, Bobbio E, Thoirleifsson S, Zeijlon R, Gudmundursson T, Wernbom M, Lindahl B, Polte CL, Omerovic E, Hammarsten O, and Redfors B
- Subjects
- Humans, Animals, Rats, Troponin I, Biomarkers, Necrosis, Troponin T, ST Elevation Myocardial Infarction, Myocardial Ischemia diagnosis, Coronary Artery Disease
- Abstract
Aims: Cardiac troponin T (cTnT) and troponin I (cTnI) are expressed as an obligate 1:1 complex in the myocardium. However, blood levels of cTnI often rise much higher than that of cTnT in myocardial infarction (MI), whereas cTnT is often higher in patients with stable conditions such as atrial fibrillation. Here we examine high-sensitive (hs) cTnI and hs-cTnT after different durations of experimental cardiac ischaemia., Methods and Results: hs-cTnI, hs-cTnT, and the hs-cTnT/hs-cTnI ratio were measured in plasma samples from rats before and at 30 and 120 min after 5, 10, 15, and 30 min of myocardial ischaemia. The animals were killed after 120 min of reperfusion, and the infarct volume and volume at risk were measured. hs-cTnI, hs-cTnT, and the hs-cTnT/hs-cTnI ratio were also measured in plasma samples collected from patients with ST-elevation myocardial infarction (STEMI). hs-cTnT and hs-cTnI increased over 10-fold in all rats subjected to ischaemia. The increase of hs-cTnI and hs-cTnT after 30 min was similar, resulting in a hs-cTnI/hs-cTnT ratio around 1. The hs-cTnI/hs-cTnT ratio was also around 1 in blood samples collected at 120 min in rats subjected to 5 or 10 min of ischaemia where no localized necrosis was observed. In contrast, the hs-cTnI/hs-cTnT ratio at 2 h was 3.6-5.5 after longer ischaemia that induced cardiac necrosis. The large hs-cTnI/hs-cTnT ratio was confirmed in patients with anterior STEMI., Conclusion: Both hs-cTnI and hs-cTnT increased similarly after brief periods of ischaemia that did not cause overt necrosis, whereas the hs-cTnI/hs-cTnT ratio tended to increase following longer ischaemia that induced substantial necrosis. A low hs-cTnI/hs-cTnT ratio around 1 may signify non-necrotic cTn release., Competing Interests: Conflict of interest: None declared., (© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2023
- Full Text
- View/download PDF
9. Trends in survival after cardiac arrest: a Swedish nationwide study over 30 years.
- Author
-
Jerkeman M, Sultanian P, Lundgren P, Nielsen N, Helleryd E, Dworeck C, Omerovic E, Nordberg P, Rosengren A, Hollenberg J, Claesson A, Aune S, Strömsöe A, Ravn-Fischer A, Friberg H, Herlitz J, and Rawshani A
- Subjects
- Female, Humans, Heart Arrest epidemiology, Heart Arrest therapy
- Abstract
Aims: Trends in characteristics, management, and survival in out-of-hospital cardiac arrest (OHCA) and in-hospital cardiac arrest (IHCA) were studied in the Swedish Cardiopulmonary Resuscitation Registry (SCRR)., Methods and Results: The SCRR was used to study 106 296 cases of OHCA (1990-2020) and 30 032 cases of IHCA (2004-20) in whom resuscitation was attempted. In OHCA, survival increased from 5.7% in 1990 to 10.1% in 2011 and remained unchanged thereafter. Odds ratios [ORs, 95% confidence interval (CI)] for survival in 2017-20 vs. 1990-93 were 2.17 (1.93-2.43) overall, 2.36 (2.07-2.71) for men, and 1.67 (1.34-2.10) for women. Survival increased for all aetiologies, except trauma, suffocation, and drowning. OR for cardiac aetiology in 2017-20 vs. 1990-93 was 0.45 (0.42-0.48). Bystander cardiopulmonary resuscitation increased from 30.9% to 82.2%. Shockable rhythm decreased from 39.5% in 1990 to 17.4% in 2020. Use of targeted temperature management decreased from 42.1% (2010) to 18.2% (2020). In IHCA, OR for survival in 2017-20 vs. 2004-07 was 1.18 (1.06-1.31), showing a non-linear trend with probability of survival increasing by 46.6% during 2011-20. Myocardial ischaemia or infarction as aetiology decreased during 2004-20 from 67.4% to 28.3% [OR 0.30 (0.27-0.34)]. Shockable rhythm decreased from 37.4% to 23.0% [OR 0.57 (0.51-0.64)]. Approximately 90% of survivors (IHCA and OHCA) had no or mild neurological sequelae., Conclusion: Survival increased 2.2-fold in OHCA during 1990-2020 but without any improvement in the final decade, and 1.2-fold in IHCA during 2004-20, with rapid improvement the last decade. Cardiac aetiology and shockable rhythms were halved. Neurological outcome has not improved., Competing Interests: Conflict of interest: none declared., (© The Author(s) 2022. Published by Oxford University Press on behalf of European Society of Cardiology.)
- Published
- 2022
- Full Text
- View/download PDF
10. Glucosylceramide synthase deficiency in the heart compromises β1-adrenergic receptor trafficking.
- Author
-
Andersson L, Cinato M, Mardani I, Miljanovic A, Arif M, Koh A, Lindbom M, Laudette M, Bollano E, Omerovic E, Klevstig M, Henricsson M, Fogelstrand P, Swärd K, Ekstrand M, Levin M, Wikström J, Doran S, Hyötyläinen T, Sinisalu L, Orešič M, Tivesten Å, Adiels M, Bergo MO, Proia R, Mardinoglu A, Jeppsson A, Borén J, and Levin MC
- Subjects
- Animals, Cardiomegaly, Mice, Receptors, Adrenergic, Glucosyltransferases genetics, Myocytes, Cardiac
- Abstract
Aims: Cardiac injury and remodelling are associated with the rearrangement of cardiac lipids. Glycosphingolipids are membrane lipids that are important for cellular structure and function, and cardiac dysfunction is a characteristic of rare monogenic diseases with defects in glycosphingolipid synthesis and turnover. However, it is not known how cardiac glycosphingolipids regulate cellular processes in the heart. The aim of this study is to determine the role of cardiac glycosphingolipids in heart function., Methods and Results: Using human myocardial biopsies, we showed that the glycosphingolipids glucosylceramide and lactosylceramide are present at very low levels in non-ischaemic human heart with normal function and are elevated during remodelling. Similar results were observed in mouse models of cardiac remodelling. We also generated mice with cardiomyocyte-specific deficiency in Ugcg, the gene encoding glucosylceramide synthase (hUgcg-/- mice). In 9- to 10-week-old hUgcg-/- mice, contractile capacity in response to dobutamine stress was reduced. Older hUgcg-/- mice developed severe heart failure and left ventricular dilatation even under baseline conditions and died prematurely. Using RNA-seq and cell culture models, we showed defective endolysosomal retrograde trafficking and autophagy in Ugcg-deficient cardiomyocytes. We also showed that responsiveness to β-adrenergic stimulation was reduced in cardiomyocytes from hUgcg-/- mice and that Ugcg knockdown suppressed the internalization and trafficking of β1-adrenergic receptors., Conclusions: Our findings suggest that cardiac glycosphingolipids are required to maintain β-adrenergic signalling and contractile capacity in cardiomyocytes and to preserve normal heart function., (© The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology.)
- Published
- 2021
- Full Text
- View/download PDF
11. Long-term mortality in patients with ischaemic heart failure revascularized with coronary artery bypass grafting or percutaneous coronary intervention: insights from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR).
- Author
-
Völz S, Redfors B, Angerås O, Ioanes D, Odenstedt J, Koul S, Valeljung I, Dworeck C, Hofmann R, Hansson E, Venetsanos D, Ulvenstam A, Jernberg T, Råmunddal T, Pétursson P, Fröbert O, Erlinge D, Jeppsson A, and Omerovic E
- Subjects
- Aged, Coronary Angiography, Coronary Artery Bypass, Female, Humans, Male, Middle Aged, Registries, Sweden epidemiology, Treatment Outcome, Angioplasty, Balloon, Coronary, Coronary Artery Disease complications, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease surgery, Heart Failure, Percutaneous Coronary Intervention
- Abstract
Aims: To compare coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI) for treatment of patients with heart failure due to ischaemic heart disease., Methods and Results: We analysed all-cause mortality following CABG or PCI in patients with heart failure with reduced ejection fraction and multivessel disease (coronary artery stenosis >50% in ≥2 vessels or left main) who underwent coronary angiography between 2000 and 2018 in Sweden. We used a propensity score-adjusted logistic and Cox proportional-hazards regressions and instrumental variable model to adjust for known and unknown confounders. Multilevel modelling was used to adjust for the clustering of observations in a hierarchical database. In total, 2509 patients (82.9% men) were included; 35.8% had diabetes and 34.7% had a previous myocardial infarction. The mean age was 68.1 ± 9.4 years (47.8% were >70 years old), and 64.9% had three-vessel or left main disease. Primary designated therapy was PCI in 56.2% and CABG in 43.8%. Median follow-up time was 3.9 years (range 1 day to 10 years). There were 1010 deaths. Risk of death was lower after CABG than after PCI [odds ratio (OR) 0.62; 95% confidence interval (CI) 0.41-0.96; P = 0.031]. The risk of death increased linearly with quintiles of hospitals in which PCI was the preferred method for revascularization (OR 1.27, 95% CI 1.17-1.38, Ptrend < 0.001)., Conclusion: In patients with ischaemic heart failure, long-term survival was greater after CABG than after PCI., (© The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology.)
- Published
- 2021
- Full Text
- View/download PDF
12. Cardiac arrest in COVID-19: characteristics and outcomes of in- and out-of-hospital cardiac arrest. A report from the Swedish Registry for Cardiopulmonary Resuscitation.
- Author
-
Sultanian P, Lundgren P, Strömsöe A, Aune S, Bergström G, Hagberg E, Hollenberg J, Lindqvist J, Djärv T, Castelheim A, Thorén A, Hessulf F, Svensson L, Claesson A, Friberg H, Nordberg P, Omerovic E, Rosengren A, Herlitz J, and Rawshani A
- Subjects
- Aged, Aged, 80 and over, COVID-19 complications, Cardiopulmonary Resuscitation, Female, Heart Arrest etiology, Humans, Male, Middle Aged, Out-of-Hospital Cardiac Arrest etiology, Registries, Survival Rate, Sweden, COVID-19 mortality, Heart Arrest mortality
- Abstract
Aim: To study the characteristics and outcome among cardiac arrest cases with COVID-19 and differences between the pre-pandemic and the pandemic period in out-of-hospital cardiac arrest (OHCA) and in-hospital cardiac arrest (IHCA)., Method and Results: We included all patients reported to the Swedish Registry for Cardiopulmonary Resuscitation from 1 January to 20 July 2020. We defined 16 March 2020 as the start of the pandemic. We assessed overall and 30-day mortality using Cox regression and logistic regression, respectively. We studied 1946 cases of OHCA and 1080 cases of IHCA during the entire period. During the pandemic, 88 (10.0%) of OHCAs and 72 (16.1%) of IHCAs had ongoing COVID-19. With regards to OHCA during the pandemic, the odds ratio for 30-day mortality in COVID-19-positive cases, compared with COVID-19-negative cases, was 3.40 [95% confidence interval (CI) 1.31-11.64]; the corresponding hazard ratio was 1.45 (95% CI 1.13-1.85). Adjusted 30-day survival was 4.7% for patients with COVID-19, 9.8% for patients without COVID-19, and 7.6% in the pre-pandemic period. With regards to IHCA during the pandemic, the odds ratio for COVID-19-positive cases, compared with COVID-19-negative cases, was 2.27 (95% CI 1.27-4.24); the corresponding hazard ratio was 1.48 (95% CI 1.09-2.01). Adjusted 30-day survival was 23.1% in COVID-19-positive cases, 39.5% in patients without COVID-19, and 36.4% in the pre-pandemic period., Conclusion: During the pandemic phase, COVID-19 was involved in at least 10% of all OHCAs and 16% of IHCAs, and, among COVID-19 cases, 30-day mortality was increased 3.4-fold in OHCA and 2.3-fold in IHCA., (© The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology.)
- Published
- 2021
- Full Text
- View/download PDF
13. Prognostic impact of percutaneous coronary intervention in octogenarians with non-ST elevation myocardial infarction: A report from SWEDEHEART.
- Author
-
Völz S, Petursson P, Angerås O, Odenstedt J, Ioanes D, Haraldsson I, Dworeck C, Hirlekar G, Redfors B, Myredal A, Libungan B, Albertsson P, Råmunddal T, and Omerovic E
- Subjects
- Aged, 80 and over, Denmark epidemiology, Female, Humans, Male, Non-ST Elevated Myocardial Infarction surgery, Prognosis, Retrospective Studies, Risk Factors, Survival Rate trends, Non-ST Elevated Myocardial Infarction mortality, Percutaneous Coronary Intervention methods, Propensity Score, Registries
- Abstract
Aims: Percutaneous coronary intervention (PCI) improves outcomes in non-ST elevation acute coronary syndromes (NSTE-ACSs). Octogenarians, however, were underrepresented in the pivotal trials. This study aimed to assess the effect of PCI in patients ≥80 years old., Methods and Results: We used data from the SWEDEHEART registry for all hospital admissions at eight cardiac care centres within Västra Götaland County. Consecutive patients ≥80 years old admitted for NSTE-ACS between January 2000 and December 2011 were included. We performed instrumental variable analysis with propensity score. The primary endpoint was all-cause mortality at 30 days and one year after index hospitalization. During the study period 5200 patients fulfilled the inclusion criteria. In total, 586 (11.2%) patients underwent PCI, the remaining 4613 patients were treated conservatively. Total mortality at 30 days was 19.4% (1007 events) and 39.4% (1876 events) at one year. Thirty-day mortality was 20.7% in conservatively treated patients and 8.5% in the PCI group (adjusted odds ratio 0.34; 95% confidence interval 0.12-0.97, p = 0.044). One-year mortality was 42.1% in the conservatively treated group and 16.3% in the PCI group (adjusted odds ratio 0.97; 95% confidence interval 0.36-2.51, p = 0.847)., Conclusions: PCI in octogenarians with NSTE-ACS was associated with a lower risk of mortality at 30 days. However, this survival benefit was not sustained during the entire study-period of one-year.
- Published
- 2020
- Full Text
- View/download PDF
14. Radial artery access is associated with lower mortality in patients undergoing primary PCI: a report from the SWEDEHEART registry.
- Author
-
Dworeck C, Redfors B, Völz S, Haraldsson I, Angerås O, Råmunddal T, Ioanes D, Myredal A, Odenstedt J, Hirlekar G, Koul S, Fröbert O, Linder R, Venetsanos D, Hofmann R, Ulvenstam A, Petursson P, Sarno G, James S, Erlinge D, and Omerovic E
- Subjects
- Aged, Female, Follow-Up Studies, Hospital Mortality trends, Humans, Male, Radial Artery, Retrospective Studies, Risk Assessment methods, Risk Factors, ST Elevation Myocardial Infarction surgery, Survival Rate trends, Sweden epidemiology, Treatment Outcome, Cardiac Catheterization methods, Percutaneous Coronary Intervention methods, Propensity Score, Registries, ST Elevation Myocardial Infarction mortality
- Abstract
Objectives: The purpose of this observational study was to evaluate the effects of radial artery access versus femoral artery access on the risk of 30-day mortality, inhospital bleeding and cardiogenic shock in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention., Methods: We used data from the SWEDEHEART registry and included all patients who were treated with primary percutaneous coronary intervention in Sweden between 2005 and 2016. We compared patients who had percutaneous coronary intervention by radial access versus femoral access with regard to the primary endpoint of all-cause death within 30 days, using a multilevel propensity score adjusted logistic regression which included hospital as a random effect., Results: During the study period, 44,804 patients underwent primary percutaneous coronary intervention of whom 24,299 (54.2%) had radial access and 20,505 (45.8%) femoral access. There were 2487 (5.5%) deaths within 30 days, of which 920 (3.8%) occurred in the radial access and 1567 (7.6%) in the femoral access group. After propensity score adjustment, radial access was associated with a lower risk of death (adjusted odds ratio (OR) 0.70, 95% confidence interval (CI) 0.55-0.88, P = 0.025). We found no interaction between access site and age, gender and cardiogenic shock regarding 30-day mortality. Radial access was also associated with a lower adjusted risk of bleeding (adjusted OR 0.45, 95% CI 0.25-0.79, P = 0.006) and cardiogenic shock (adjusted OR 0.41, 95% CI 0.24-0.73, P = 0.002)., Conclusions: In patients with ST-elevation myocardial infarction, primary percutaneous coronary intervention by radial access rather than femoral access was associated with an adjusted lower risk of death, bleeding and cardiogenic shock. Our findings are consistent with, and add external validity to, recent randomised trials.
- Published
- 2020
- Full Text
- View/download PDF
15. Relationship between degree of heparin anticoagulation and clinical outcome in patients receiving potent P2Y12-inhibitors with no planned glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention in acute myocardial infarction: a VALIDATE-SWEDEHEART substudy.
- Author
-
Sharma T, Rylance R, Karlsson S, Koul S, Venetsanos D, Omerovic E, Fröbert O, Persson J, James S, and Erlinge D
- Subjects
- Aged, Aged, 80 and over, Anticoagulants adverse effects, Coronary Thrombosis etiology, Coronary Thrombosis prevention & control, Drug Monitoring, Female, Hemorrhage chemically induced, Heparin adverse effects, Humans, Male, Middle Aged, Myocardial Infarction diagnosis, Myocardial Infarction mortality, Platelet Aggregation Inhibitors adverse effects, Purinergic P2Y Receptor Antagonists adverse effects, Recurrence, Registries, Risk Assessment, Risk Factors, Sweden, Time Factors, Treatment Outcome, Whole Blood Coagulation Time, Anticoagulants administration & dosage, Heparin administration & dosage, Myocardial Infarction therapy, Percutaneous Coronary Intervention adverse effects, Percutaneous Coronary Intervention mortality, Platelet Aggregation Inhibitors administration & dosage, Purinergic P2Y Receptor Antagonists administration & dosage
- Abstract
Aims: Heparin is the preferred choice of anticoagulant in percutaneous coronary intervention (PCI) for acute myocardial infarction (MI). An established dosage of heparin has not yet been determined, but treatment may be optimized through monitoring of activated clotting time (ACT). The aim of this study was to determine the relationship between heparin dose or ACT with a composite outcome of death, MI, or bleeding using data from the registry-based, randomized, controlled, and open-label VALIDATE-SWEDEHEART trial, although patients were not randomized to heparin dose in this substudy., Methods and Results: Patients with MI undergoing PCI and receiving treatment with a potent P2Y12-inhibitor and anticoagulation with heparin, without the planned use of glycoprotein IIb/IIIa inhibitor (GPI), were enrolled in this substudy. The primary endpoint was a composite endpoint of death, MI, and bleeding at 30 days. The individual components and stent thrombosis were analysed separately. We divided patients into groups according to the initial dose of unfractionated heparin during PCI (<70 U/kg, 70-100 U/kg, and >100 U/kg) or ACT (ACT <250 s, 250-350 s, and >350 s) as well as investigating them as continuous variables in Cox proportional hazards models using univariable and multivariable analyses. No major differences were noted between heparin stratified in groups (P = 0.22) or heparin as a continuous variable in relation to the primary composite endpoint hazard ratio (HR) 1.0 confidence interval (CI) (0.99-1.01) for heparin dose/kg. No differences were found between ACT stratified in groups (P = 0.453) or ACT in seconds HR 1.0 CI (0.99-1.00) regarding the primary endpoint. The individual components of death, MI, major bleeding, and stent thrombosis were not significantly different across heparin doses or ACT levels either., Conclusion: We found no association between heparin dose or ACT levels and death, MI bleeding complications, or stent thrombosis. Therefore, there is no strong support for a specific heparin dose or mandatory ACT monitoring in patients treated with potent P2Y12-inhibitors with no planned GPI., (Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2020
- Full Text
- View/download PDF
16. Bivalirudin versus heparin monotherapy in non-ST-segment elevation myocardial infarction.
- Author
-
Erlinge D, Koul S, Omerovic E, Fröbert O, Linder R, Danielewicz M, Hamid M, Venetsanos D, Henareh L, Pettersson B, Wagner H, Grimfjärd P, Jensen J, Hofmann R, Ulvenstam A, Völz S, Petursson P, Östlund O, Sarno G, Wallentin L, Scherstén F, Eriksson P, and James S
- Subjects
- Aged, Anticoagulants therapeutic use, Female, Hemorrhage epidemiology, Heparin therapeutic use, Hirudins, Humans, Male, Myocardial Infarction epidemiology, Platelet Aggregation Inhibitors therapeutic use, Platelet Glycoprotein GPIIb-IIIa Complex antagonists & inhibitors, Prasugrel Hydrochloride therapeutic use, Purinergic P2Y Receptor Antagonists therapeutic use, Recombinant Proteins therapeutic use, Stents adverse effects, Sweden epidemiology, Thrombosis, Ticagrelor therapeutic use, Antithrombins therapeutic use, Non-ST Elevated Myocardial Infarction drug therapy, Peptide Fragments therapeutic use, Percutaneous Coronary Intervention methods
- Abstract
Background: The optimal anti-coagulation strategy for patients with non-ST-elevation myocardial infarction treated with percutaneous coronary intervention is unclear in contemporary clinical practice of radial access and potent P2Y12-inhibitors. The aim of this study was to investigate whether bivalirudin was superior to heparin monotherapy in patients with non-ST-elevation myocardial infarction without routine glycoprotein IIb/IIIa inhibitor use., Methods: In a large pre-specified subgroup of the multicentre, prospective, randomised, registry-based, open-label clinical VALIDATE-SWEDEHEART trial we randomised patients with non-ST-elevation myocardial infarction undergoing percutaneous coronary intervention, treated with ticagrelor or prasugrel, to bivalirudin or heparin monotherapy with no planned use of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention. The primary endpoint was the rate of a composite of all-cause death, myocardial infarction or major bleeding within 180 days., Results: A total of 3001 patients with non-ST-elevation myocardial infarction, were enrolled. The primary endpoint occurred in 12.1% (182 of 1503) and 12.5% (187 of 1498) of patients in the bivalirudin and heparin groups, respectively (hazard ratio of bivalirudin compared to heparin treatment 0.96, 95% confidence interval 0.78-1.18, p =0.69). The results were consistent in all major subgroups. All-cause death occurred in 2.0% versus 1.7% (hazard ratio 1.15, 0.68-1.94, p =0.61), myocardial infarction in 2.3% versus 2.5% (hazard ratio 0.91, 0.58-1.45, p =0.70), major bleeding in 8.9% versus 9.1% (hazard ratio 0.97, 0.77-1.24, p =0.82) and definite stent thrombosis in 0.3% versus 0.2% (hazard ratio 1.33, 0.30-5.93, p =0.82)., Conclusion: Bivalirudin as compared to heparin during percutaneous coronary intervention for non-ST-elevation myocardial infarction did not reduce the composite of all-cause death, myocardial infarction or major bleeding in non-ST-elevation myocardial infarction patients receiving current recommended treatments with modern P2Y12-inhibitors and predominantly radial access.
- Published
- 2019
- Full Text
- View/download PDF
17. Radial versus femoral access in patients with acute coronary syndrome undergoing invasive management: A prespecified subgroup analysis from VALIDATE-SWEDEHEART.
- Author
-
Völz S, Angerås O, Koul S, Haraldsson I, Sarno G, Venetsanos D, Grimfärd P, Ulvenstam A, Hofmann R, Hamid M, Henareh L, Wagner H, Jensen J, Danielewicz M, Östlund O, Eriksson P, Scherstén F, Linder R, Råmunddal T, Pétursson P, Fröbert O, James S, Erlinge D, and Omerovic E
- Subjects
- Acute Coronary Syndrome complications, Aged, Anticoagulants therapeutic use, Antithrombins therapeutic use, Female, Hemorrhage epidemiology, Heparin therapeutic use, Hirudins, Humans, Male, Myocardial Infarction epidemiology, Non-ST Elevated Myocardial Infarction drug therapy, Peptide Fragments therapeutic use, Percutaneous Coronary Intervention trends, Prospective Studies, Recombinant Proteins therapeutic use, Registries, ST Elevation Myocardial Infarction drug therapy, Treatment Outcome, Acute Coronary Syndrome therapy, Femoral Artery surgery, Percutaneous Coronary Intervention methods, Radial Artery surgery
- Abstract
Aims: In the Bivalirudin versus Heparin in ST-Segment and Non-ST-Segment Elevation Myocardial Infarction in Patients on Modern Antiplatelet Therapy in the Swedish Web System for Enhancement and Development of Evidence-based Care in Heart Disease Evaluated according to Recommended Therapies Registry Trial (VALIDATE-SWEDEHEART), bivalirudin was not superior to unfractionated heparin in patients with acute coronary syndrome undergoing invasive management. We assessed whether the access site had an impact on the primary endpoint of death, myocardial infarction or major bleeding at 180 days and whether it interacted with bivalirudin/unfractionated heparin., Methods and Results: A total of 6006 patients with acute coronary syndrome planned for percutaneous coronary intervention were randomised to either bivalirudin or unfractionated heparin. Arterial access was left to the operator discretion. Overall, 90.5% of patients underwent transradial access and 9.5% transfemoral access. Baseline risk was higher in transfemoral access. The unadjusted hazard ratio for the primary outcome was lower with transradial access (hazard ratio 0.53, 95% confidence interval 0.43-0.67, p <0.001) and remained lower after multivariable adjustment (hazard ratio 0.56, 95% confidence interval 0.52-0.84, p <0.001). Transradial access was associated with lower risk of death (hazard ratio 0.41, 95% confidence interval 0.28-0.60, p <0.001) and major bleeding (hazard ratio 0.57, 95% confidence interval 0.44-0.75, p <0.001). There was no interaction between treatment with bivalirudin and access site for the primary endpoint ( p =0.976) or major bleeding ( p =0.801)., Conclusions: Transradial access was associated with lower risk of death, myocardial infarction or major bleeding at 180 days. Bivalirudin was not associated with less bleeding, irrespective of access site.
- Published
- 2019
- Full Text
- View/download PDF
18. Pretreatment with P2Y12 receptor antagonists in ST-elevation myocardial infarction: a report from the Swedish Coronary Angiography and Angioplasty Registry.
- Author
-
Redfors B, Dworeck C, Haraldsson I, Angerås O, Odenstedt J, Ioanes D, Petursson P, Völz S, Albertsson P, Råmunddal T, Persson J, Koul S, Erlinge D, and Omerovic E
- Subjects
- Aged, Aged, 80 and over, Clopidogrel therapeutic use, Female, Hemorrhage epidemiology, Humans, Male, Middle Aged, Outcome Assessment, Health Care, Percutaneous Coronary Intervention adverse effects, Prasugrel Hydrochloride therapeutic use, Registries, ST Elevation Myocardial Infarction mortality, ST Elevation Myocardial Infarction physiopathology, Stents adverse effects, Survival Rate, Sweden epidemiology, Thrombosis epidemiology, Ticagrelor therapeutic use, Angioplasty standards, Coronary Angiography standards, Percutaneous Coronary Intervention methods, Purinergic P2Y Receptor Antagonists therapeutic use, ST Elevation Myocardial Infarction therapy
- Abstract
Aims: Pretreatment of patients with ST-elevation myocardial infarction (STEMI) with P2Y12 receptor antagonists is supported by guidelines and is a common practice despite the lack of definite evidence for its benefit., Methods and Results: Using data from the Swedish Coronary Angiography and Angioplasty Registry on procedures between 2005 and 2016, we stratified all patients who underwent primary percutaneous coronary intervention due to STEMI in Sweden by whether or not they were pretreated with P2Y12 receptor antagonists. We investigated associations between pretreatment with P2Y12 receptor antagonists and the risk of adverse outcomes using propensity score-adjusted mixed-effects logistic regression, which accounted for clustering of patients within hospitals. The primary endpoint was all-cause death within 30 days. Secondary endpoints were infarct-related artery (IRA) occlusion, 30-day stent thrombosis, in-hospital bleeding, neurological complications, and cardiogenic shock. In total, 44 804 patients were included. They were treated with clopidogrel (N = 26 136, 58.3%), ticagrelor (N = 15 792, 35.3%), or prasugrel (N = 2352, 5.3%); 37 840 (84.5%) were pretreated, and 30 387 (67.8%) had IRA occlusion. At 30 days, there were 2488 (5.6%) deaths and 267 (0.6%) stent thrombosis. Pretreatment was not associated with better survival at 30 days [odds ratio (OR) 1.08, 95% confidence interval (CI) 0.95-1.24; P = 0.313], reduced IRA occlusion (OR 0.98, 95% CI 0.92-1.05; P = 0.608), decreased stent thrombosis (OR 0.99, 95% CI 0.69-1.43; P = 0.932), higher risk of in-hospital bleeding (OR 1.05, 95% CI 0.89-1.26; P = 0.526), or neurological complications (OR 0.72, 95% CI 0.43-1.21; P = 0.210)., Conclusion: Pretreatment of STEMI patients with P2Y12 receptor antagonists was not associated with improved clinical outcomes., (Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2019
- Full Text
- View/download PDF
19. Fractional flow reserve-guided percutaneous coronary intervention vs. medical therapy for patients with stable coronary lesions: meta-analysis of individual patient data.
- Author
-
Zimmermann FM, Omerovic E, Fournier S, Kelbæk H, Johnson NP, Rothenbühler M, Xaplanteris P, Abdel-Wahab M, Barbato E, Høfsten DE, Tonino PAL, Boxma-de Klerk BM, Fearon WF, Køber L, Smits PC, De Bruyne B, Pijls NHJ, Jüni P, and Engstrøm T
- Subjects
- Female, Humans, Male, Middle Aged, Myocardial Infarction, Prognosis, Randomized Controlled Trials as Topic, Coronary Artery Disease diagnosis, Coronary Artery Disease mortality, Coronary Artery Disease therapy, Fractional Flow Reserve, Myocardial physiology, Percutaneous Coronary Intervention adverse effects, Percutaneous Coronary Intervention mortality, Percutaneous Coronary Intervention statistics & numerical data
- Abstract
Aims: To assess the effect of fractional flow reserve (FFR)-guided percutaneous coronary intervention (PCI) with contemporary drug-eluting stents on the composite of cardiac death or myocardial infarction (MI) vs. medical therapy in patients with stable coronary lesions., Methods and Results: We performed a systematic review and meta-analysis of individual patient data (IPD) of the three available randomized trials of contemporary FFR-guided PCI vs. medical therapy for patients with stable coronary lesions: FAME 2 (NCT01132495), DANAMI-3-PRIMULTI (NCT01960933), and Compare-Acute (NCT01399736). FAME 2 enrolled patients with stable coronary artery disease (CAD), while the other two focused on non-culprit lesions in stabilized patients after acute coronary syndrome. A total of 2400 subjects were recruited from 54 sites world-wide with 1056 randomly assigned to FFR-guided PCI and 1344 to medical therapy. The pre-specified primary outcome was a composite of cardiac death or MI. We included data from extended follow-ups for FAME 2 (up to 5.5 years follow-up) and DANAMI-3-PRIMULTI (up to 4.7 years follow-up). After a median follow-up of 35 months (interquartile range 12-60 months), a reduction in the composite of cardiac death or MI was observed with FFR-guided PCI as compared with medical therapy (hazard ratio 0.72, 95% confidence interval 0.54-0.96; P = 0.02). The difference between groups was driven by MI., Conclusion: In this IPD meta-analysis of the three available randomized controlled trials to date, FFR-guided PCI resulted in a reduction of the composite of cardiac death or MI compared with medical therapy, which was driven by a decreased risk of MI.
- Published
- 2019
- Full Text
- View/download PDF
20. Oxygen therapy in ST-elevation myocardial infarction.
- Author
-
Hofmann R, Witt N, Lagerqvist B, Jernberg T, Lindahl B, Erlinge D, Herlitz J, Alfredsson J, Linder R, Omerovic E, Angerås O, Venetsanos D, Kellerth T, Sparv D, Lauermann J, Barmano N, Verouhis D, Östlund O, Svensson L, and James SK
- Subjects
- Aged, Air, Female, Humans, Male, Middle Aged, Mortality, Patient Readmission, Percutaneous Coronary Intervention, Prosthesis Failure, Shock, Cardiogenic etiology, Stents adverse effects, Thrombosis etiology, Oxygen Inhalation Therapy, ST Elevation Myocardial Infarction therapy
- Abstract
Aims: To determine whether supplemental oxygen in patients with ST-elevation myocardial infarction (STEMI) impacts on procedure-related and clinical outcomes., Methods and Results: The DETermination of the role of Oxygen in suspected Acute Myocardial Infarction (DETO2X-AMI) trial randomized patients with suspected myocardial infarction (MI) to receive oxygen at 6 L/min for 6-12 h or ambient air. In this pre-specified analysis, we included only STEMI patients who underwent percutaneous coronary intervention (PCI). In total, 2807 patients were included, 1361 assigned to receive oxygen, and 1446 assigned to ambient air. The pre-specified primary composite endpoint of all-cause death, rehospitalization with MI, cardiogenic shock, or stent thrombosis at 1 year occurred in 6.3% (86 of 1361) of patients allocated to oxygen compared to 7.5% (108 of 1446) allocated to ambient air [hazard ratio (HR) 0.85, 95% confidence interval (95% CI) 0.64-1.13; P = 0.27]. There was no difference in the rate of death from any cause (HR 0.86, 95% CI 0.61-1.22; P = 0.41), rate of rehospitalization for MI (HR 0.92, 95% CI 0.57-1.48; P = 0.73), rehospitalization for cardiogenic shock (HR 1.05, 95% CI 0.21-5.22; P = 0.95), or stent thrombosis (HR 1.27, 95% CI 0.46-3.51; P = 0.64). The primary composite endpoint was consistent across all subgroups, as well as at different time points, such as during hospital stay, at 30 days and the total duration of follow-up up to 1356 days., Conclusions: Routine use of supplemental oxygen in normoxemic patients with STEMI undergoing primary PCI did not significantly affect 1-year all-cause death, rehospitalization with MI, cardiogenic shock, or stent thrombosis.
- Published
- 2018
- Full Text
- View/download PDF
21. International Expert Consensus Document on Takotsubo Syndrome (Part II): Diagnostic Workup, Outcome, and Management.
- Author
-
Ghadri JR, Wittstein IS, Prasad A, Sharkey S, Dote K, Akashi YJ, Cammann VL, Crea F, Galiuto L, Desmet W, Yoshida T, Manfredini R, Eitel I, Kosuge M, Nef HM, Deshmukh A, Lerman A, Bossone E, Citro R, Ueyama T, Corrado D, Kurisu S, Ruschitzka F, Winchester D, Lyon AR, Omerovic E, Bax JJ, Meimoun P, Tarantini G, Rihal C, Y-Hassan S, Migliore F, Horowitz JD, Shimokawa H, Lüscher TF, and Templin C
- Subjects
- Humans, Algorithms, Arrhythmias, Cardiac etiology, Computed Tomography Angiography, Coronary Angiography, Disease Management, Echocardiography, Electrocardiography, Magnetic Resonance Imaging, Myocardial Perfusion Imaging, Recurrence, Treatment Outcome, Takotsubo Cardiomyopathy complications, Takotsubo Cardiomyopathy diagnosis, Takotsubo Cardiomyopathy therapy
- Abstract
The clinical expert consensus statement on takotsubo syndrome (TTS) part II focuses on the diagnostic workup, outcome, and management. The recommendations are based on interpretation of the limited clinical trial data currently available and experience of international TTS experts. It summarizes the diagnostic approach, which may facilitate correct and timely diagnosis. Furthermore, the document covers areas where controversies still exist in risk stratification and management of TTS. Based on available data the document provides recommendations on optimal care of such patients for practising physicians.
- Published
- 2018
- Full Text
- View/download PDF
22. International Expert Consensus Document on Takotsubo Syndrome (Part I): Clinical Characteristics, Diagnostic Criteria, and Pathophysiology.
- Author
-
Ghadri JR, Wittstein IS, Prasad A, Sharkey S, Dote K, Akashi YJ, Cammann VL, Crea F, Galiuto L, Desmet W, Yoshida T, Manfredini R, Eitel I, Kosuge M, Nef HM, Deshmukh A, Lerman A, Bossone E, Citro R, Ueyama T, Corrado D, Kurisu S, Ruschitzka F, Winchester D, Lyon AR, Omerovic E, Bax JJ, Meimoun P, Tarantini G, Rihal C, Y-Hassan S, Migliore F, Horowitz JD, Shimokawa H, Lüscher TF, and Templin C
- Subjects
- Age Distribution, Catecholamines metabolism, Coronary Artery Disease physiopathology, Coronary Vasospasm physiopathology, Humans, Mental Disorders epidemiology, Microcirculation, Nervous System Diseases epidemiology, Plaque, Atherosclerotic physiopathology, Risk Factors, Sex Distribution, Takotsubo Cardiomyopathy epidemiology, Takotsubo Cardiomyopathy metabolism, Terminology as Topic, Takotsubo Cardiomyopathy diagnosis, Takotsubo Cardiomyopathy physiopathology
- Abstract
Takotsubo syndrome (TTS) is a poorly recognized heart disease that was initially regarded as a benign condition. Recently, it has been shown that TTS may be associated with severe clinical complications including death and that its prevalence is probably underestimated. Since current guidelines on TTS are lacking, it appears timely and important to provide an expert consensus statement on TTS. The clinical expert consensus document part I summarizes the current state of knowledge on clinical presentation and characteristics of TTS and agrees on controversies surrounding TTS such as nomenclature, different TTS types, role of coronary artery disease, and etiology. This consensus also proposes new diagnostic criteria based on current knowledge to improve diagnostic accuracy.
- Published
- 2018
- Full Text
- View/download PDF
23. Impact of long-term stress in Takotsubo syndrome: Experience of patients.
- Author
-
Wallström S, Ulin K, Määttä S, Omerovic E, and Ekman I
- Subjects
- Emotions, Female, Humans, Male, Stress, Psychological, Takotsubo Cardiomyopathy psychology
- Abstract
Background: The connection between stress and disease has been part of folk wisdom for a long time and has even made its way into our language with phrases such as 'scared to death' and 'a broken heart'. Takotsubo syndrome is a form of acute, reversible heart failure characterized by ballooning of the left ventricle. Post-menopausal women are primarily affected, but cases have been described in both sexes and at all ages. The complete pathophysiology is unknown, but the disease has been connected to psychological or physical stress and a surge in catecholamines. Despite the strong connection with stress, knowledge about the life of patients before the onset of Takotsubo syndrome is lacking., Aim: The aim of this study was to describe and interpret patients' narratives about long-term stress experienced before the onset of Takotsubo syndrome., Method: Nineteen people diagnosed with Takotsubo syndrome were interviewed. The narrative interviews were recorded and transcribed verbatim. The resulting texts were analysed using phenomenological hermeneutics., Results: The analysis revealed that the interviewees lived under stressful circumstances, characterized by feeling burdened by responsibilities, injustice and uncertainty, long before the onset of Takotsubo syndrome. This long-term stress wore down the defences of the interviewees to the degree that their capacity was exhausted and the smallest stressor could 'tip them over the edge'. The findings indicated that the social structure of gender possibly contributed to the interviewees' condition., Conclusions: These findings indicated that long-term stressful circumstances may cause vulnerability to acute psychological or physical stressors and, subsequently, to the onset of Takotsubo syndrome., Competing Interests: The authors declare that there is no conflict of interest., (© The European Society of Cardiology 2015.)
- Published
- 2016
- Full Text
- View/download PDF
24. Outcomes in patients treated with ticagrelor or clopidogrel after acute myocardial infarction: experiences from SWEDEHEART registry.
- Author
-
Sahlén A, Varenhorst C, Lagerqvist B, Renlund H, Omerovic E, Erlinge D, Wallentin L, James SK, and Jernberg T
- Subjects
- Acute Coronary Syndrome, Adenosine analogs & derivatives, Clopidogrel, Humans, Platelet Aggregation Inhibitors, Prospective Studies, Registries, Ticagrelor, Ticlopidine analogs & derivatives, Treatment Outcome, Myocardial Infarction
- Abstract
Aims: Ticagrelor reduces ischaemic events and mortality in acute coronary syndrome (ACS) vs. clopidogrel. We wished to study clinical outcomes in a large real-world population post-ACS., Methods and Results: We performed a prospective cohort study in 45 073 ACS patients enrolled into Swedish Web system for Enhancement and Development of Evidence-based care in Heart Disease Evaluated According to Recommended Therapies who were discharged on ticagrelor (N = 11 954) or clopidogrel (N = 33 119) between 1 January 2010 and 31 December 2013. The primary outcome was a composite of all-cause death, re-admission with myocardial infarction (MI) or stroke, secondary outcomes as the individual components of the primary outcome, and re-admission with bleeding. The risk of the primary outcome with ticagrelor vs. clopidogrel was 11.7 vs. 22.3% (adjusted hazard ratio (HR) 0.85 [95% confidence interval: 0.78-0.93]), risk of death 5.8 vs. 12.9% (adjusted HR 0.83 [0.75-0.92]), and risk of MI 6.1 vs. 10.8% (adjusted HR 0.89 [0.78-1.01]) at 24 months. Re-admission with bleeding with ticagrelor vs. clopidogrel occurred in 5.5 vs. 5.2% (adjusted HR 1.20 [1.04-1.40]). In a subset of patients undergoing percutaneous coronary intervention (PCI) on ticagrelor vs. clopidogrel the PCI-related in-hospital bleeding was 3.7 vs. 2.7% (adjusted odds ratio, OR, 1.57 [1.30-1.90])., Conclusion: Ticagrelor vs. clopidogrel post-ACS was associated with a lower risk of death, MI, or stroke, as well as death alone. Risk of bleeding was higher with ticagrelor. These real-world outcomes are consistent with randomized trial results., (Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2016. For permissions please email: journals.permissions@oup.com.)
- Published
- 2016
- Full Text
- View/download PDF
25. Radial artery intima-media thickness predicts major cardiovascular events in patients with suspected coronary artery disease.
- Author
-
Eklund C, Omerovic E, Haraldsson I, Friberg P, and Gan LM
- Subjects
- Acute Coronary Syndrome epidemiology, Age Factors, Aged, Case-Control Studies, Coronary Angiography methods, Coronary Artery Disease epidemiology, Female, Humans, Incidence, Kaplan-Meier Estimate, Logistic Models, Male, Middle Aged, Multivariate Analysis, Myocardial Perfusion Imaging methods, Predictive Value of Tests, Prognosis, Proportional Hazards Models, Prospective Studies, Reference Values, Risk Assessment, Severity of Illness Index, Sex Factors, Tunica Intima pathology, Tunica Media pathology, Ultrasonography, Interventional, Acute Coronary Syndrome diagnosis, Coronary Artery Disease diagnostic imaging, Radial Artery diagnostic imaging, Tunica Intima diagnostic imaging, Tunica Media diagnostic imaging
- Abstract
Aims: In the present study, we investigated the prognostic value of radial artery intima-media thickness (rIMT) in patients with suspected coronary artery disease (CAD). Carotid artery intima-media thickness is a well-known surrogate marker of atherosclerosis. Recently, using very high-resolution ultrasound, we showed rIMT can be imaged with great precision and is related to various cardiovascular risk factors., Methods and Results: We recruited a total of 416 patients (62 ± 9 years, 44% male) with suspected CAD, referred to myocardial perfusion scintigraphy (MPS). Among these patients, 133 underwent coronary angiography on clinical indication. Two-dimensional images of carotid and radial arteries were acquired bilaterally (using 8 and 55 MHz ultrasound, respectively). All patients were followed regarding major adverse cardiovascular events (MACE), including cardiovascular death, myocardial infarction, stroke, and coronary revascularization. A group of 20 healthy subjects (aged 61 ± 3, 50% male) were recruited for reference. During 3 years of follow-up, 77 MACE occurred. Patients with MACE exhibited significantly thicker rIMT vs. those without (0.35 ± 0.06 vs. 0.32 ± 0.07 mm, P < 0.001). Increased rIMT was associated with an increased occurrence of significant coronary artery narrowing, diagnosed by coronary angiography (P = 0.028). Patients with rIMT values above the median had a nearly three-fold increased risk for MACE (hazard ratio 2.8, 95% confidence interval 1.6-4.8). In multivariate analysis, rIMT (P = 0.011) remained a significant predictor of MACE, along with type II diabetes (P = 0.012), body mass index (P = 0.024), and MPS-verified ischaemia (P < 0.001)., Conclusion: Radial artery IMT, assessed by very high-resolution ultrasound, confers prognostic information in patients with suspected CAD., (Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2014. For permissions please email: journals.permissions@oup.com.)
- Published
- 2014
- Full Text
- View/download PDF
26. Takotsubo cardiomyopathy: an integrated multi-imaging approach.
- Author
-
Bossone E, Lyon A, Citro R, Athanasiadis A, Meimoun P, Parodi G, Cimarelli S, Omerovic E, Ferrara F, Limongelli G, Cittadini A, Salerno-Uriarte JA, Perrone Filardi P, Schneider B, Sechtem U, and Erbel R
- Subjects
- Algorithms, Coronary Angiography methods, Fluorodeoxyglucose F18, Humans, Incidence, Magnetic Resonance Imaging, Myocardial Infarction diagnosis, Positron-Emission Tomography, Prognosis, Radiopharmaceuticals, Risk Factors, Takotsubo Cardiomyopathy physiopathology, Tomography, Emission-Computed, Single-Photon, Ventricular Dysfunction, Left physiopathology, Echocardiography methods, Echocardiography, Three-Dimensional methods, Electrocardiography methods, Takotsubo Cardiomyopathy diagnosis
- Abstract
Takotsubo cardiomyopathy (TTC) is a distinct clinical entity characterized by the presence of transient left ventricular wall dysfunction without significant culprit obstructive coronary artery disease. Invasive coronary angiography and ventriculography are the 'gold standard' for definitive diagnosis, with an integrated multi-modality imaging approach offering advantages in various clinical scenarios. Echocardiography is a widely available, first-line, non-invasive imaging technique appropriate both in emergency setting to confirm diagnosis, assess for various potential acute complications, and in serial follow-up to track myocardial recovery. Cardiac magnetic resonance (CMR) may be helpful to discriminate TTC from other acute cardiac syndromes with troponin elevation and ventricular dysfunction. Echocardiography, CMR, and nuclear imaging may also provide new insights into possible underlying pathophysiological mechanisms, and myocardial (123)I-metaiodobenzyl-guanidine imaging may have a role for retrospective diagnosis in the subacute phase of late-presenting cases. The potential diagnostic role of coronary computed tomography angiography in the emergency room requires a further study.
- Published
- 2014
- Full Text
- View/download PDF
27. Contrast echocardiography reveals apparently normal coronary perfusion in a rat model of stress-induced (Takotsubo) cardiomyopathy.
- Author
-
Redfors B, Shao Y, Wikström J, Lyon AR, Oldfors A, Gan LM, and Omerovic E
- Subjects
- Animals, Contrast Media, Disease Models, Animal, Image Processing, Computer-Assisted, Isoproterenol pharmacology, Rats, Sprague-Dawley, Reproducibility of Results, Takotsubo Cardiomyopathy physiopathology, Coronary Circulation physiology, Echocardiography methods, Takotsubo Cardiomyopathy diagnostic imaging
- Abstract
Aims: Stress-induced cardiomyopathy (SIC) is an important differential diagnosis to acute myocardial infarction (AMI) that is associated with significant morbidity and mortality. The typical hallmark of SIC is left-ventricular apical akinesia but preserved function in basal segments. Catecholamines are postulated to play an important role in SIC but the precise pathophysiology is incompletely understood. Whether myocardial perfusion of the affected segments is impaired in SIC has been debated and remains unknown., Methods and Results: Myocardial contrast echocardiography (MCE) was used to study regional myocardial perfusion in a rat model of SIC. Twelve rats received 50 mg/kg isoproterenol (ISO) i.p. and were continuously monitored by MCE. Apical and basal perfusion were estimated and expressed as a ratio at baseline, 5, 10, 20, 30, 40, 50, 60, 70, 80, and 90 min post-ISO. The rats developed typical apical ballooning after 43 ± 9 min post-ISO injection. The ratio of apical:basal perfusion was close to 1.00 at all time-points and never dropped below 0.89 (95% CI never extended below 0.73). Light and electron microcoscopical investigation revealed no structural damage of myocardial vessels., Conclusion: Apical perfusion is not impaired in the early phase of SIC in this rat model.
- Published
- 2014
- Full Text
- View/download PDF
28. Normal apical myocardial perfusion in the rat model with Takotsubo syndrome: is subsequent microvascular dysfunction and hypoperfusion an epiphenomenon? Reply.
- Author
-
Redfors B, Shao Y, Oldfors A, and Omerovic E
- Subjects
- Animals, Coronary Circulation physiology, Echocardiography methods, Takotsubo Cardiomyopathy diagnostic imaging
- Published
- 2014
- Full Text
- View/download PDF
29. Evidence for obesity paradox in patients with acute coronary syndromes: a report from the Swedish Coronary Angiography and Angioplasty Registry.
- Author
-
Angerås O, Albertsson P, Karason K, Råmunddal T, Matejka G, James S, Lagerqvist B, Rosengren A, and Omerovic E
- Subjects
- Acute Coronary Syndrome complications, Aged, Coronary Angiography, Female, Humans, Kaplan-Meier Estimate, Male, Obesity complications, Registries, Sweden epidemiology, Acute Coronary Syndrome mortality, Body Mass Index, Obesity mortality
- Abstract
Aims: The obesity paradox refers to the epidemiological evidence that obesity compared with normal weight is associated with counter-intuitive improved health in a variety of disease conditions. The aim of this study was to investigate the relationship between body mass index (BMI) and mortality in patients with acute coronary syndromes (ACSs)., Methods and Results: We extracted data from the Swedish Coronary Angiography and Angioplasty Registry and identified 64 436 patients who underwent coronary angiography due to ACSs. In 54 419 (84.4%) patients, a significant coronary stenosis was identified, whereas 10 017 (15.6%) patients had no significant stenosis. Patients were divided into nine different BMI categories. The patients with significant stenosis were further subdivided according to treatment received such as medical therapy, percutaneous coronary intervention (PCI), or coronary artery by-pass grafting. Mortality for the different subgroups during a maximum of 3 years was compared using Cox proportional hazards regression with the lean BMI category (21.0 to <23.5 kg/m(2)) as the reference group. Regardless of angiographic findings [significant or no significant coronary artery disease (CAD)] and treatment decision, the underweight group (BMI <18.5 kg/m(2)) had the greatest risk for mortality. Medical therapy and PCI-treated patients with modest overweight (BMI category 26.5-<28 kg/m(2)) had the lowest risk of mortality [hazard ratio (HR) 0.52; 95% CI 0.34-0.80 and HR 0.64; 95% CI 0.50-0.81, respectively]. When studying BMI as a continuous variable in patients with significant CAD, the adjusted risk for mortality decreased with increasing BMI up to ~35 kg/m(2) and then increased. In patients with significant CAD undergoing coronary artery by-pass grafting and in patients with no significant CAD, there was no difference in mortality risk in the overweight groups compared with the normal weight group., Conclusion: In this large and unselected group of patients with ACSs, the relation between BMI and mortality was U-shaped, with the nadir among overweight or obese patients and underweight and normal-weight patients having the highest risk. These data strengthen the concept of the obesity paradox substantially.
- Published
- 2013
- Full Text
- View/download PDF
30. Lower risk of stent thrombosis and restenosis with unrestricted use of 'new-generation' drug-eluting stents: a report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR).
- Author
-
Sarno G, Lagerqvist B, Fröbert O, Nilsson J, Olivecrona G, Omerovic E, Saleh N, Venetzanos D, and James S
- Subjects
- Aged, Angioplasty, Balloon, Coronary methods, Blood Vessel Prosthesis, Coronary Stenosis therapy, Drug-Eluting Stents statistics & numerical data, Epidemiologic Methods, Female, Humans, Male, Middle Aged, Prosthesis Failure, Stents adverse effects, Stents statistics & numerical data, Sweden, Treatment Outcome, Coronary Restenosis prevention & control, Drug-Eluting Stents adverse effects, Graft Occlusion, Vascular prevention & control
- Abstract
Aims: To compare the long-term outcome after percutaneous coronary intervention with 'new-generation' drug-eluting stents (n-DES) to 'older generation' DES (o-DES), and bare-metal stents (BMS) in a real-world population., Methods and Results: We evaluated 94 384 consecutive stent implantations (BMS, n = 64 631; o-DES, n = 19 202; n-DES, n = 10 551) in Sweden from November 2006 to October 2010. All cases of definite stent thrombosis (ST) and restenosis were documented in the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Older generation DES were classified as: Cypher and Cypher Select (Cordis Corporation, Miami, FL, USA), Taxus Express and Taxus Liberté (Boston Scientific Corporation), and Endeavor (Medtronic Inc.) and n-DES as: Endeavor Resolute (Medtronic Inc.), XienceV, Xience Prime (Abbott Laboratories) and Promus, Promus Element (Boston Scientific Corporation). The Cox regression analyses unadjusted and adjusted for clinical and angiographic covariates showed a statistically significant lower risk of restenosis in n-DES compared with BMS [adjusted hazard ratio (HR) 0.29; 95% confidence interval (CI): 0.25-0.33] and o-DES (HR 0.62; 95% CI: 0.53-0.72). A lower risk of definite ST was found in n-DES compared with BMS (HR 0.38; 95% CI: 0.28-0.52) and o-DES (HR, 0.57; 95% CI: 0.41-0.79). The risk of death was significantly lower in n-DES compared with o-DES (adjusted HR: 0.77; 95% CI: 0.63-0.95) and BMS (adjusted HR: 0.55; 95% CI: 0.46-0.67)., Conclusion: Percutaneous coronary intervention with n-DES is associated with a 38% lower risk of clinically meaningful restenosis, a 43% lower risk of definite ST, and a 23% lower risk of death compared with o-DES in this observational study from a large real-world population.
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.